JP2017075173A5 - - Google Patents

Download PDF

Info

Publication number
JP2017075173A5
JP2017075173A5 JP2016249232A JP2016249232A JP2017075173A5 JP 2017075173 A5 JP2017075173 A5 JP 2017075173A5 JP 2016249232 A JP2016249232 A JP 2016249232A JP 2016249232 A JP2016249232 A JP 2016249232A JP 2017075173 A5 JP2017075173 A5 JP 2017075173A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
amyloidosis
condition associated
pathological condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016249232A
Other languages
English (en)
Other versions
JP2017075173A (ja
JP6370361B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017075173A publication Critical patent/JP2017075173A/ja
Publication of JP2017075173A5 publication Critical patent/JP2017075173A5/ja
Application granted granted Critical
Publication of JP6370361B2 publication Critical patent/JP6370361B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (11)

  1. Figure 2017075173
    から選択される化合物。
  2. 医薬として許容される担体、及び、
    Figure 2017075173
    から選択される化合物を含む、医薬組成物。
  3. 化合物が、
    Figure 2017075173
    である、請求項2に記載の医薬組成物。
  4. アミロイドーシスに関連する病的症状を治療するための、
    Figure 2017075173
    から選択される化合物を含む、医薬組成物。
  5. 化合物が、
    Figure 2017075173
    である、請求項4に記載の医薬組成物。
  6. アミロイドーシスに関連する病的症状に罹患している対象をアミロイド画像化するための、
    Figure 2017075173
    の構造を有する化合物を含む、医薬組成物。
  7. アミロイドーシスに関連する病的症状がアルツハイマー病である、請求項4から6のいずれか一項に記載の医薬組成物。
  8. アミロイドーシスに関連する病的症状を治療するための医薬の製造における、
    Figure 2017075173
    から選択される化合物の使用。
  9. 化合物が、
    Figure 2017075173
    である、請求項8に記載の使用。
  10. アミロイドーシスに関連する病的症状がアルツハイマー病である、請求項8または9に記載の使用。
  11. 治療が斑の形成を阻害する、請求項8から10のいずれか一項に記載の使用。
JP2016249232A 2008-03-21 2016-12-22 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物 Active JP6370361B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3857108P 2008-03-21 2008-03-21
US61/038,571 2008-03-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014046341A Division JP6140090B2 (ja) 2008-03-21 2014-03-10 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物

Publications (3)

Publication Number Publication Date
JP2017075173A JP2017075173A (ja) 2017-04-20
JP2017075173A5 true JP2017075173A5 (ja) 2017-11-24
JP6370361B2 JP6370361B2 (ja) 2018-08-08

Family

ID=41091569

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011501009A Active JP5501339B2 (ja) 2008-03-21 2009-03-23 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物
JP2014046341A Active JP6140090B2 (ja) 2008-03-21 2014-03-10 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物
JP2016249232A Active JP6370361B2 (ja) 2008-03-21 2016-12-22 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011501009A Active JP5501339B2 (ja) 2008-03-21 2009-03-23 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物
JP2014046341A Active JP6140090B2 (ja) 2008-03-21 2014-03-10 アルツハイマー病及び関連疾患の検出及び治療のための化合物及び組成物

Country Status (9)

Country Link
US (5) US8450466B2 (ja)
EP (2) EP3231804B1 (ja)
JP (3) JP5501339B2 (ja)
CN (2) CN102046638B (ja)
AU (1) AU2009225407B2 (ja)
CA (2) CA2718035C (ja)
HK (2) HK1157323A1 (ja)
MX (1) MX2010010314A (ja)
WO (1) WO2009117728A2 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8450466B2 (en) * 2008-03-21 2013-05-28 The General Hosptial Corporation Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
NZ607257A (en) * 2010-08-16 2015-02-27 Cognoptix Inc System and method for detecting amyloid proteins
CA2824858A1 (en) * 2011-01-18 2012-07-26 General Atomics Hydrolase enzyme substrates and uses thereof
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
ES2749096T3 (es) 2012-10-25 2020-03-19 Massachusetts Gen Hospital Terapias de combinación para el tratamiento de la enfermedad de Alzheimery transtornos relacionados
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
ES2946754T3 (es) 2014-03-19 2023-07-25 Amydis Diagnostics Inc Agentes para detección de amiloides y métodos para utilizar los mismos
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
US10675365B2 (en) 2016-09-29 2020-06-09 Korea Atomic Energy Research Institute Curcumin derivative, method for producing same, and photo-acoustic imaging agent comprising same for detecting beta-amyloid plaque
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ, インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
CA3105392A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
BR112021003156A2 (pt) 2018-08-23 2021-05-11 Seagen, Inc. composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit.
WO2023150739A2 (en) * 2022-02-07 2023-08-10 Moskovitz Martin J Cryo-surgical device and materials and method of use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1009897A (en) 1911-03-27 1911-11-28 Us Electrographic Company Projection apparatus.
CH375356A (de) 1959-03-25 1964-02-29 Sandoz Ag Verfahren zur Herstellung von neuen substituierten Succinimiden
CH449628A (de) * 1962-04-16 1968-01-15 Sandoz Ag Verfahren zur Herstellung substituierter Succinimide
US3207780A (en) * 1962-11-15 1965-09-21 Upjohn Co 1-deoxy-1-guanidino-3-o-carbamoyl-scyllo-inositol and acylates thereof
US4069262A (en) 1977-03-07 1978-01-17 E. I. Du Pont De Nemours And Company Preparation of 2-fluoronitrobenzene
FR2498594A1 (fr) 1981-01-23 1982-07-30 Rhone Poulenc Ind Procede de preparation de monoesters d'acides carboxyliques b,g-insatures
US4446123A (en) 1982-10-13 1984-05-01 Hahnemann University Process of radioimaging the myocardium of mammals utilizing radiolabeled lipophilic cations
NL8401907A (nl) * 1983-06-27 1985-01-16 Sandoz Ag Spirosuccinimiden en werkwijzen voor het bereiden en toepassen van deze spirosuccinimiden.
BE900003A (fr) * 1983-06-27 1984-12-27 Sandoz Sa Derives du spirosuccinimide utilisables comme medicaments.
US4606908A (en) 1983-10-04 1986-08-19 Washington Research Foundation Methods and compositions for plasma and organ imaging
EP0273659A1 (en) * 1986-12-27 1988-07-06 Takeda Chemical Industries, Ltd. Azaspiro compounds, their production and use
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US5852029A (en) * 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
SE9002117L (sv) 1990-06-14 1991-08-26 Nils Elander Mikrovaagsanordning foer behandling av precessvaetskor
US5139034A (en) * 1990-11-15 1992-08-18 Philip Morris Incorporated Smoking compositions containing a menthol-release additive
IT1244546B (it) * 1991-02-01 1994-07-15 Mediolanum Farmaceutici Spa Analoghi del fosfatidilinositolo inibitori della fosfolipasi c fosfatidilinositolo-specifica
US5315043A (en) 1992-02-05 1994-05-24 E. I. Du Pont De Nemours And Company Aromatic nucleophilic fluorination
US5264570A (en) * 1992-08-05 1993-11-23 General Electric Company Method for making 2-[18 F]fluoro-2-deoxy-D-glucose
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
AU1529297A (en) 1996-01-24 1997-08-20 Warner-Lambert Company Method of imaging amyloid deposits
JP3816570B2 (ja) * 1996-02-16 2006-08-30 塩水港精糖株式会社 アシル化剤
TW593290B (en) 1996-05-10 2004-06-21 Janssen Pharmaceutica Nv Alkylaminobenzothiazole and -benzoxazole derivatives
DE19624705A1 (de) * 1996-06-20 1998-01-08 Deutsches Krebsforsch Dendrimere auf Saccharid-Basis
US5817877A (en) 1996-09-23 1998-10-06 Yale University Metal-catalyzed amination of organic sulfonates to organic amines
US6187286B1 (en) 1996-12-27 2001-02-13 The General Hospital Corporation Tumor imaging agents, methods and kits
US6019957A (en) 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
CA2302837A1 (en) 1997-09-08 1999-03-18 The General Hospital Corporation Imaging agents for early detection and monitoring of cardiovascular plaque
JP4177472B2 (ja) * 1997-10-02 2008-11-05 株式会社横浜国際バイオ研究所 窒素官能基を含有するアシル化剤及びその製造法
US6660832B1 (en) 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
DE60019622T2 (de) 1999-09-13 2006-03-02 Pola Chemical Industries, Inc. Nitroimidazolderivate und diese enthaltende diagnostische bilderzeugungsmittel
EP1294663B1 (en) 2000-06-12 2004-05-06 University of Florida Research Foundation Fluorinated benzene manufacturing process
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
CA2444214A1 (en) 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
TWI266634B (en) 2002-02-06 2006-11-21 Univ Johns Hopkins Non-invasive diagnostic imaging technology for mitochondria dysfunction using radiolabeled lipophilic salts
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
CN100536837C (zh) * 2003-02-27 2009-09-09 乔安妮·麦克劳林 鲨肌醇在制备诊断试剂中的用途
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0304640D0 (en) 2003-02-28 2003-04-02 Novartis Ag Organic compounds
US7295831B2 (en) 2003-08-12 2007-11-13 3E Technologies International, Inc. Method and system for wireless intrusion detection prevention and security management
AU2003304416A1 (en) 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
WO2005082425A1 (en) 2004-02-24 2005-09-09 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
KR100578732B1 (ko) * 2004-03-05 2006-05-12 학교법인 포항공과대학교 분자 수송체로서의 이노시톨 유도체 및 이의 제조방법
CN101072591A (zh) * 2004-11-05 2007-11-14 惠氏公司 用于筛选阿尔茨海默病治疗剂的pet和磁共振
WO2006053428A1 (en) 2004-11-17 2006-05-26 Joanne Mclaurin Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation
US7138540B1 (en) 2005-09-06 2006-11-21 Institute Of Nuclear Energy Research Convenient method for the preparation of new precursor of no-carrier-added O-(2-[18F]fluoroethyl)-L-Tyrosine)
US20070111970A1 (en) * 2005-10-13 2007-05-17 Antonio Cruz Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence
JP2007194369A (ja) * 2006-01-18 2007-08-02 Toei Kogyo Kk 高出力Er:YAGレーザ装置
NO325976B1 (no) * 2006-01-26 2008-08-25 Gba Marine As Anordning for absorpsjon av gass eller damp i vaeske og fremgangsmate ved reintrodusering av damp eller gass i vaeske som gassen eller dampen stammer fra
US20070197452A1 (en) 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
JP2010520229A (ja) 2007-03-01 2010-06-10 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 放射性弗素化方法
WO2009014203A1 (ja) * 2007-07-26 2009-01-29 Hokko Chemical Industry Co., Ltd. (1,3,5/2,4,6)-1-フルオロ-2,3,4,5,6-シクロヘキサンペントールの製造方法
US8450466B2 (en) 2008-03-21 2013-05-28 The General Hosptial Corporation Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
CA2747575A1 (en) 2008-12-22 2010-07-01 Keith Graham A method for synthesis of a radionuclide-labeled compound using an exchange resin
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
US20150246142A1 (en) 2012-09-25 2015-09-03 The Regents Of The University Of Michigan Imaging agents
US20170334804A1 (en) 2014-10-31 2017-11-23 The General Hospital Corporation F-18 labeled tracer and methods of manufacture

Similar Documents

Publication Publication Date Title
JP2017075173A5 (ja)
CL2019001978A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.
RU2017112747A (ru) Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
JP2015501783A5 (ja)
JP2016518337A5 (ja)
JP2017509667A5 (ja)
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
JP2019526543A5 (ja)
JP2016522254A5 (ja)
JP2014507446A5 (ja)
JP2013525444A5 (ja)
MX2021000538A (es) Uso de sobetirome en el tratamiento de enfermedades de mielinizacion.
JP2017506624A5 (ja)
RU2017105353A (ru) Соединения
MD3478712T2 (ro) Anticorpi peptidici beta amiloizi anti-N3pGlu și utilizări ale acestora
JP2019516739A5 (ja)
JP2019529514A5 (ja)
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2016512817A5 (ja)
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
JP2015516419A5 (ja)
JP2016501219A5 (ja)
MX2021002322A (es) Nuevos metodos.
JP2009178162A5 (ja)